媒體聲音 | 藥明康德一體化CRDMO如何助力北歐創(chuàng)新發(fā)展？

編者按：

也許許多人沒有關(guān)注到，在遙遠(yuǎn)的北歐，醫(yī)藥創(chuàng)新正在迸發(fā)出蓬勃而強(qiáng)勁的活力。
以斯堪的納維亞半島為例，這個(gè)坐落在歐洲西北角的地區(qū)由挪威、瑞典、丹麥等多國(guó)組成。一方面，當(dāng)?shù)貙W(xué)術(shù)資源雄厚，科研兼具深度與全球影響力；另一方面，當(dāng)?shù)貐R聚了生物創(chuàng)新研究所（BioInnovation Institute）、生物醫(yī)藥谷（Medicon Valley）等諸多孵化器，不僅加速了創(chuàng)新研究的轉(zhuǎn)化，更孕育出一大批新興生物科技企業(yè)。
近日，藥明康德新藥發(fā)現(xiàn)業(yè)務(wù)副總裁Dave Madge博士接受歐洲行業(yè)媒體《北歐生命科學(xué)新聞》（Nordic Life Science News）的采訪，他為斯堪的納維亞半島地區(qū)的創(chuàng)新活力而感到振奮，也提到，無(wú)論是初創(chuàng)企業(yè)，還是大型制藥公司，藥明康德的一體化CRDMO平臺(tái)都能為他們創(chuàng)造價(jià)值，助力當(dāng)?shù)貏?chuàng)新生態(tài)圈的發(fā)展。
“讓天下沒有難做的藥，難治的病”，這是藥明康德的愿景。作為一家合同研究、開發(fā)和生產(chǎn)組織（CRDMO），我們致力于助力藥企加速研發(fā)進(jìn)程，為有需要的患者帶來更多突破性療法。
以下是報(bào)道全文。

作為一家全球化運(yùn)營(yíng)的CRDMO公司，藥明康德能夠?yàn)闅W洲、亞洲和北美創(chuàng)新生態(tài)圈提供端到端的醫(yī)藥研發(fā)生產(chǎn)服務(wù)。僅2024年，藥明康德就助力了30多個(gè)國(guó)家的數(shù)千名客戶的科學(xué)轉(zhuǎn)化和研發(fā)進(jìn)程。其獨(dú)特的一體化平臺(tái)能夠?yàn)樗幬镩_發(fā)的每個(gè)階段提供解決方案，覆蓋從早期發(fā)現(xiàn)、臨床前測(cè)試、臨床開發(fā)和商業(yè)化生產(chǎn)的全流程，助力切實(shí)有效的療法盡快抵達(dá)患者。

藥明康德也持續(xù)在歐洲建能力，擴(kuò)規(guī)模，目前有位于德國(guó)和瑞士的兩個(gè)研發(fā)生產(chǎn)基地，從而更好地幫助當(dāng)?shù)乜蛻簟?/p>

其中，在斯堪的納維亞半島，藥明康德正通過完善的運(yùn)營(yíng)體系為此地約60家公司提供臨床前新藥發(fā)現(xiàn)服務(wù)。Dave Madge博士密切關(guān)注北歐地區(qū)的發(fā)展，他認(rèn)為這里的生命科學(xué)領(lǐng)域正在發(fā)生許多振奮人心的變化。

▲圖片來源：藥明康德慕尼黑基地

“由于越來越多的風(fēng)險(xiǎn)投資公司在斯堪的納維亞半島扎根，這里已經(jīng)成為一個(gè)充滿創(chuàng)新活力的區(qū)域，新興公司不斷涌現(xiàn)，丹麥和瑞典的創(chuàng)新孵化器數(shù)量同樣在增加。這些孵化器為將學(xué)術(shù)界的早期概念轉(zhuǎn)化為切實(shí)有效的療法帶來了新的機(jī)遇和策略。這也是我們希望做出積極貢獻(xiàn)的方向。”Dave Madge博士解釋道。

“從投資、基礎(chǔ)設(shè)施建設(shè)，到經(jīng)驗(yàn)豐富的藥物研發(fā)科學(xué)家擁抱新興企業(yè)的熱情和多元化創(chuàng)新的程度，斯堪的納維亞半島致力于加速早期創(chuàng)新轉(zhuǎn)化的決心已經(jīng)在諸多方面得到了充分體現(xiàn)。過去五六年間，我們有幸親眼目睹了這一激動(dòng)人心的進(jìn)程。”他進(jìn)一步說道。

這些變化不僅體現(xiàn)在哥本哈根的生物創(chuàng)新研究所和靈北孵化器（Lundbeck Incubator），也體現(xiàn)在瑞典的SMILE創(chuàng)業(yè)中心（SMILE Venture Hub）和生物醫(yī)藥谷。當(dāng)參觀這些機(jī)構(gòu)時(shí)，人們會(huì)立刻被入駐企業(yè)的科研質(zhì)量、熱情和協(xié)作精神所震撼。

▲圖片來源：藥明康德慕尼黑基地

Dave Madge博士認(rèn)為，無(wú)論是初創(chuàng)企業(yè)，還是大型制藥公司，作為一體化CRDMO公司，藥明康德正在為當(dāng)?shù)貏?chuàng)新生態(tài)圈的合作伙伴提供助力。對(duì)于規(guī)模較小的公司，賦能他們高效、低成本地獲取資源和技術(shù)意義重大，一旦新數(shù)據(jù)證明其能驅(qū)動(dòng)策略、提振信心，企業(yè)便可借助藥明康德的平臺(tái)迅速驗(yàn)證創(chuàng)新想法。“我們?yōu)榭蛻籼峁┝四茏屗麄儨y(cè)試和完善想法的平臺(tái)，助力將創(chuàng)新項(xiàng)目快速推進(jìn)到下一個(gè)價(jià)值創(chuàng)造拐點(diǎn)，最終讓更多創(chuàng)新療法惠及患者。”Dave Madge博士說道。

“藥物發(fā)現(xiàn)的過程是非常復(fù)雜的，它依賴于許多不同的能力技術(shù)，并且在不同的治療領(lǐng)域、不同的策略和藥物類型下，差異很大。但是，有些技術(shù)可以滿足不同的新藥早期發(fā)現(xiàn)需求，幫助新興公司逾越那些復(fù)雜、高投入的障礙。”Dave Madge博士解釋道。

“我們的主要貢獻(xiàn)之一是對(duì)新能力、新技術(shù)進(jìn)行早期建設(shè)投入，賦能不同客戶加速他們的創(chuàng)新項(xiàng)目。作為一個(gè)體量較大的平臺(tái)，我們有能力做到這一點(diǎn)，并且能夠以更大的規(guī)模效應(yīng)分?jǐn)偝杀荆鴮?duì)于小型公司來說，專門開發(fā)這些技術(shù)平臺(tái)，對(duì)于經(jīng)濟(jì)成本和資源善用，都將存在挑戰(zhàn)。”Dave Madge博士說道。

From discovery to delivery: Inside WuXi AppTec’s Global CRDMO Model

EVERY DRUG can be made and every disease can be treated. That’s the vision of WuXi AppTec, the contract research, development and manufacturing organization (CRDMO) that helps accelerate timelines to bring breakthrough treatments to the patients who need them most.

As a global CRDMO, WuXi AppTec offers end-to-end pharmaceutical services across Europe, Asia, and North America. In 2024 alone, it has helped thousands of customers in over 30 countries transform scientific discoveries into breakthrough therapies. Its integrated platform provides solutions for every stage of drug development, from early discovery and preclinical testing to clinical development and commercial manufacturing, with the goal of getting effective treatments to patients faster.

The company is dedicated to building its platform in Europe in order to support clients locally, anchored by two European sites – one in Germany and one in Switzerland – to facilitate that.

Across Scandinavia, WuXi AppTec is well established and currently serves around 60 companies in pre-clinical drug discovery. Dave Madge, Vice President of Discovery Services, keeps a close eye on the Northern European region, where he feels that a lot of impressive things are happening in life sciences.

“It’s a dynamic landscape with increasing numbers of early-stage companies, since there are more venture capital firms that are building a footprint in Scandinavia, and we also see expansion in the number of incubators in Denmark and Sweden. These bring new opportunities and strategies to translate early-stage ideas from academia towards therapies. That’s a direction that we’re very well plugged into,” Dave Madge explains.

“The dedication in Scandinavia to accelerate the translation of early-stage ideas into patient therapies has been well demonstrated in terms of investment, the provision of infrastructure, and the rate at which experienced drug discovery scientists are embracing the excitement and diversity of early-stage companies. It’s a fantastic change over the last 5-6 years that’s been happening in front of our eyes,” he says.

This is apparent not only with the BioInnovation Institute and Lundbeck Incubator in Copenhagen, but also with the SMILE Venture Hub and Medicon Village in Sweden. When you visit these organisations you are immediately struck by the quality of the science going on and the enthusiasm and collaborative spirit of the tenants.

Dave is well aware of the impact WuXi AppTec, as a CRDMO, has on the life sciences ecosystem from start-ups to big pharma. For smaller companies rapid and cost-effective access to resources and technology is a critical enabling tool – allowing many ideas to be rapidly evaluated at a time when new data can have a dramatic impact on confidence and strategy.

“We provide our clients with a platform to test and refine their ideas, and then to rapidly develop them to value inflexion points, which ultimately leads to more innovative treatments reaching the patients,” comments Dave.

“Drug discovery is very complex, dependent on many different technologies, and very diverse in terms of different therapeutic areas, different strategies and different types of drugs that can be developed. But there are technologies that can be brought to bear to facilitate and accelerate drug discovery across all the different stages and across all this diversity. For small companies, that’s a complex, and capital-intensive, landscape to navigate,” Dave Madge explains.

“One of our major contributions is early investment into technology platforms which are then made available to all our clients, to facilitate and accelerate their programs. As a big company we can afford to do that, we can afford to distribute the cost across our larger client base, whereas for smaller companies it’s simply not capital efficient or good use of their resources to develop those platforms,” Dave Madge says.

免責(zé)聲明：本文僅作信息交流之目的，文中觀點(diǎn)不代表藥明康德立場(chǎng)，亦不代表藥明康德支持或反對(duì)文中觀點(diǎn)。本文也不是治療方案推薦。如需獲得治療方案指導(dǎo)，請(qǐng)前往正規(guī)醫(yī)院就診。

版權(quán)說明：歡迎個(gè)人轉(zhuǎn)發(fā)至朋友圈，謝絕媒體或機(jī)構(gòu)未經(jīng)授權(quán)以任何形式轉(zhuǎn)載至其他平臺(tái)。轉(zhuǎn)載授權(quán)請(qǐng)?jiān)凇杆幟骺档隆刮⑿殴娞?hào)回復(fù)“轉(zhuǎn)載”，獲取轉(zhuǎn)載須知。